Association between beta2-microglobulin normalisation within 6 months of ibrutinib-based treatment and progression-free survival in patients with chronic lymphocytic leukaemia

Trial Profile

Association between beta2-microglobulin normalisation within 6 months of ibrutinib-based treatment and progression-free survival in patients with chronic lymphocytic leukaemia

Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Nov 2015

At a glance

  • Drugs Ibrutinib (Primary) ; Cyclophosphamide; Fludarabine; Rituximab
  • Indications Chronic lymphocytic leukaemia
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Nov 2015 New trial record
    • 20 Nov 2015 Results published in the Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top